

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
04 July 2019 (04.07.2019)



(10) International Publication Number
WO 2019/133961 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) C07K 16/46 (2006.01)

C07K 16/30 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2018/068118

(22) International Filing Date:

31 December 2018 (31.12.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/612,242 29 December 2017 (29.12.2017) US

62/687,063 19 June 2018 (19.06.2018) US

(71) Applicants: **AMGEN INC.** [US/US]; One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (US). **AMGEN RESEARCH (MUNICH) GMBH** [DE/DE]; Staffelseestrasse 2, 81477 Munich (DE).

(72) Inventors: **RAUM, Tobias**; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE). **ARVEDSON, Tara**; 323 Nevada Avenue, Moss Beach, CA 93048 (US). **BAILIS, Julie**; 111 Wilder Avenue, Los Gatos, CA 95030 (US). **DAHLHOFF, Christoph**; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE). **ROSS, Sandra**; 587 Colina Vista, Ventura, CA 93003 (US). **CHEN, Irwin**; 1875 Kelton Avenue, #202, Los Angeles, CA 90025 (US). **BLÜMEL, Claudia**; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE). **NAHRWOLD, Elisabeth**; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE). **PENDZIALEK, Jochen**; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE). **WAHL, Joachim**; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE).

(74) Agent: **JANULIS, Lynn, L.**; Marshall, Gerstein & Borun LLP, 233 S. Wacker Drive, 6300 Willis Tower, Chicago, IL 60606-6357 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

WO 2019/133961 A1

(54) Title: BISPECIFIC ANTIBODY CONSTRUCT DIRECTED TO MUC17 AND CD3

(57) Abstract: The present invention provides bispecific antibody constructs characterized by comprising a first domain binding to MUC17, a second domain binding to an extracellular epitope of the human and the *Macaca* CD3e chain and optionally a third domain, which is a specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.